AUGMENT: RELAPSED/REFRACTORY INDOLENT NHL PATIENTS WERE MORE SENSITIVE TO NEXT TREATMENT FOLLOWING LENALIDOMIDE/RITUXIMAB (R2) THAN RITUXIMAB/PLACEBO
Hematological Oncology | June 12, 2019 | Volume: 37 | Issue: S2 | Pages: 227-229
10.1002/hon.42_2630